Jubilant Therapeutics Inc, a US-based, clinical-stage biopharmaceutical company that is advancing precision therapeutics for myeloproliferative neoplasms (MPNs), announced on Tuesday that clinical results from its Phase 1/2 study of JBI-802, a first-in-class, orally administered dual inhibitor of LSD1 and HDAC6 (CoREST), have been selected for an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place 12-15 December 2026, in New Orleans and online.
The oral presentation will include results from the Phase 1 portion of the study, an open-label, multicentre trial designed to evaluate the safety, tolerability and preliminary efficacy of JBI-802. The study has enrolled patients with essential thrombocythemia (ET), polycythaemia vera (PV) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) with thrombocytosis who were relapsed, refractory or intolerant to standard of care (JBI-802-02; ACTRN12624000478516).
JBI-802 is an orally administered dual inhibitor of lysine-specific demethylase 1 (LSD1) and histone deacetylase 6 (HDAC6) that targets the CoREST complex. The company says that it is designed to act on multiple disease-relevant processes, including abnormal megakaryocyte differentiation, platelet production, leukocyte proliferation and inflammatory signaling. JBI-802 is being evaluated in an ongoing Phase 1/2 study in patients with ET and other thrombocytosis-predominant myeloid malignancies (JBI-802-02; ACTRN12624000478516; NCT07612280).
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Valneva reports 94% antibody persistence five years after single-dose chikungunya vaccination
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Energenesis Biomedical presents ENERGI-based approach to space anaemia at TASTI 2026
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology